Get the Stockscreener App
1.60
3.03%
-0.05
After Hours:
1.56
-0.04
-2.50%
Mainz Biomed N V stock is traded at $1.60, with a volume of 6.70M.
It is down -3.03% in the last 24 hours and down -2.44% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
See More
Previous Close:
$1.65
Open:
$1.43
24h Volume:
6.70M
Relative Volume:
28.60
Market Cap:
$7.32M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-0.9756
EPS:
-1.64
Net Cash Flow:
$-23.84M
1W Performance:
+2.56%
1M Performance:
-2.44%
6M Performance:
-47.71%
1Y Performance:
-86.21%
1-Day Range:
$1.2801
$1.66
1-Week Range:
$1.2801
$1.75
52-Week Range:
$1.2801
$16.04
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.60 | 7.55M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
536.19 | 203.60B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
204.96 | 149.49B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
629.91 | 50.19B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
140.81 | 39.28B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
200.60 | 34.15B | 15.70B | 1.24B | 2.01B | 6.9036 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Maxim Group | Buy |
| Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Mainz Biomed reports promising results for pancreatic cancer blood test - Investing.com India
Mainz Biomed N.V. Reports Positive Results from Feasibility Study for Non-Invasive Pancreatic Cancer Screening Test - Quiver Quantitative
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - Stock Titan
What analysts say about Mainz Biomed NV stockMarket Correction Analysis & Outstanding Profit Strategies - earlytimes.in
Can Mainz Biomed N.V. recover in the next quarter2025 Analyst Calls & Verified Entry Point Detection - newser.com
Visual analytics tools that track Mainz Biomed N.V. performanceInsider Selling & AI Forecasted Stock Moves - newser.com
What MACD and RSI say about Mainz Biomed N.V.CPI Data & High Return Stock Watch Alerts - newser.com
How forex fluctuations impact Mainz Biomed N.V. (4TO) stockWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com
How Mainz Biomed N.V. (4TO) stock expands through international marketsTake Profit & Verified Momentum Stock Ideas - newser.com
Will Mainz Biomed N.V. (4TO) stock benefit from mergersWeekly Gains Report & Low Risk Entry Point Tips - newser.com
Real time breakdown of Mainz Biomed N.V. stock performance2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Real time pattern detection on Mainz Biomed N.V. stockSell Signal & Daily Growth Stock Tips - newser.com
Can swing trading help recover from Mainz Biomed N.V. lossesJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
How Mainz Biomed N.V. (4TO) stock reacts to monetary easingTrade Volume Summary & Weekly High Momentum Picks - newser.com
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting - GlobeNewswire
97% Accuracy: Mainz Biomed's Revolutionary RNA Test Could Transform Early Colorectal Cancer Detection - Stock Titan
Published on: 2025-09-30 00:50:22 - newser.com
Can Mainz Biomed N.V. (4TO) stock double in coming yearsQuarterly Trade Report & Weekly Momentum Picks - newser.com
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):